Mike V. Gormally, MD PhD
@gormallymdphd
Medical Oncologist @sloan_kettering
Scientist and Drug Discoverer in @KlebanoffLab
Vertical adventurer 🏔
ID: 1429047591426215940
21-08-2021 11:49:43
13 Tweet
116 Followers
240 Following
🚨Pre-print alert: Here, we show that CAR-T *and* CAR-NK persistence is negatively self-regulated through activation dependent FAS ligand expression. Further highlights FAS as an actionable molecule to enhance cell therapies. Parker Institute for Cancer Immunotherapy Memorial Sloan Kettering Cancer Center biorxiv.org/content/10.110…
What is the "Holy Grail" of tumor antigens❓ Found out in our lab's recent interview with The Scientist (The Scientist )👇. Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy #Tcellpower the-scientist.com/a-quest-for-th…
Excited to see our phase 2 multicenter study of Tumor-Infiltrating Lymphocyte in Advanced #LungCancer Resistant to Immunotherapy in Cancer Discovery. #TIL #Celltherapy aacrjournals.org/cancerdiscover…
So proud! Immense gratitude to Chris and the rest of the Klebanoff_Lab for such fantastic mentorship, to Conquer Cancer, the ASCO Foundation for 💸💸💸 to support us, and all cancer patients HopeForStomachCancer and beyond, whose contributions are central to how we discover novel T cell therapies⬇️⬇️⬇️
Happening now: MSK research fellow Mike V. Gormally, MD PhD presents results from a real-world analysis evaluating HLA LOH frequencies and survival outcomes in #cancer at #AACR25.
MSK physician-scientist Klebanoff_Lab talked about all things #neoantigens for the Novel Classes of Human Cancer Rejection Antigens session this morning at #AACR25.
🚨Today, in Nature Cancer, we show that CAR-T cells and CAR-NK cells contain the seeds of their own self-destruction. Disruption of a FAS-L/FAS circuit enhances CAR potency against liquid and solid cancers. rdcu.be/exjEy Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy MSK Department of Medicine
📢New MS out now, where we pair real-world clinical data from patients at Memorial Sloan Kettering Cancer Center with HLA zygosity derived from #IMPACT to detect HLA loss and its effect on survival, an increasingly important biomarker in the age of immunotherapies. jitc.bmj.com/content/13/9/e…
Tomorrow at #ESMO25: MSK’s Dr. Michael Gormally (Mike V. Gormally, MD PhD) will discuss pan-cancer mapping of HLA class I loss of #heterozygosity in a 50,000 patient cohort which reveals prognostic clinical implications for HLA-restricted therapies. ESMO - Eur. Oncology Learn more:
